WLF’s “DDMAC Watch” Objects To Vitrase Ad Division Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Including the full risk information in the “brief summary” portion of promotional materials is sufficient, Washington Legal Foundation says.
You may also be interested in...
Vitrase Journal Ad Lacks Risk Information, FDA Says
The violative ad for the spreading agent omits warnings, the Division of Drug Marketing, Advertising & Communications states.
FDA Releases DTC Guidances; "Not The Last Word" On Ads, Commissioner McClellan Says
The agency pledges further review of its guidance on direct-to-consumer advertising. Broadcast ads for drugs and enforcement actions against repeat offenders could see more attention.
India Highlights "Public Interest" To Reign In Prices For Non-Scheduled Drugs
Dr. Reddy's, GSK, Ranbaxy and UCB among manufacturers that could see prices reduced under government order that reflects issues raised in Gleevec patent dispute.